# A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

> **NCT06516978** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 528 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Orelabrutinib
- **DRUG:** Venetoclax
- **DRUG:** Chidamide
- **DRUG:** Penpulimab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06516978
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 528 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516978, "A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06516978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*